http://www.summitplc.com/
Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease Duchenne Muscular Dystrophy (DMD) and infections caused by the superbug C. difficile

:-))

Another good day.

Doing well and I did not join, should have got in weeks ago but hey ho. Well done to all that did.

Profit taking today, with the usual 10% fall after a good rise.

Target price in the short term 22p
http://onlinebusinessuniversity.blogspot.co.uk/2013/09/summit-corporation-period-of-excellent.html#chitika_close_button

I haven't been this excited by a share since Staneco and edible packaging and PDX and their Pump with no moving parts. Both of these rocketed whilst I was on board and later collasped but I was long gone...Can SUMM make it where these two failed and actually make money for the company and shareholders over the long term?
In at 4p 4.87p and 14p
Di
:-)

Posted a week ago on ll - The last target set by this guy was broken for this reason. Charts don't work with news driven stock.

The reality is that Summit's peers in the USA are valued at what would equate to 85p or higher for Summit, this is the reason for the rise, particularly as Summit is now presenting it's finding to a US audience who tend to appreciate the work of BioTechs unlike in the UK.

I expect this stock to keep rising, and if anyone of it's lead drugs makes it to the market place, then it will be £2 per share, not 85-100p and certainly way above some chartists 20p! 12p made me laugh, so does 20p!

IMHO, DYOR etc

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII


September 20, 2013 | By John Carroll




http://www.fiercebiotech.com/story/muscular-dystrophy-drug-glaxosmithkline-prosensa-fails-phiii/2013-09-20

Sad for the families, may prove very good for Summit investors. Still a way to go yet.

A lot of excitement across the boards today about this share.

No stopping this one.

Summit Corporation PLC (SUMM:LSE) set a new 52-week high during today's trading session when it reached 19.18. Over this period, the share price is up 424.14%.

Yep, indeed!...going skyhigh....just like PLE....then hopefully LBB, MDZ, PIRI, COMS, CEE, QPP amongst others (already done well with REM having bought b4 the surge and have taken profits since)

sorry, that's CCE, not CEE!

22 Aug N+1 Singer 10.70 Buy - Looking dated now the sp is at 19p . As Delia Smith would say to N+1 Singer '' Lets be aving yer''. lol

APPOINTMENT OF NOMINATED ADVISER

Oxford, UK, 26 September 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, is pleased to announce the appointment with immediate effect of Cairn Financial Advisers as the Company's Nominated Adviser (Nomad).

- END -

Summit to present at California medical congress
By John Harrington September 30 2013, 2:05pm Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.Summit is an Oxford based drug discovery and development company targeting high-value areas of unmet medical need including DMD and C. difficile infection.

Summit (LON:SUMM) is to give a presentation on one of its lead drugs at the 18th International World Muscle Society congress in California.

The poster presentation, entitled "Future clinical and biomarker development for SMT C1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy", will outline the proposed clinical development plan to achieve proof of concept for SMT C1100 in Duchenne muscular dystrophy (DMD) patients.

Summit's C1100 development drug has the potential to maintain healthy muscle tone. This offers a potential breakthrough in treating DMD, a rare wasting disease that affects boys only (and 1,500 here in the UK).

Details will also be presented on the supporting biomarker programme that aims to develop new exploratory clinical endpoints to help evaluate the benefit of therapies such as SMT C1100 in future DMD patient trials.

The Congress is taking place from 1 October to 5 October.

A copy

A link to the above :- Summit to Present Clinical and Biomarker Programmes for DMD at WMS

A copy of the presentation put on the company website today -

http://www.summitplc.com/userfiles/file/WMS%202013%20FINAL(1).pdf